Pinnacle Academic Press
Proceedings Series

Vol. 4 2025

Review **Open Access**

Application of Cell Biology and Molecular Biology Principles in Monoclonal Vaccines and Drug Delivery Systems

Mikarly Zhong [1,*]

Received: 20 May 2025
Revised: 28 May 2025
Accepted: 17 June 2025
Published: 25 July 2025

[1] Shenzhen International Foundation College, Shenzhen, Guangdong, China
* Correspondence: Mikarly Zhong, Shenzhen International Foundation College, Shenzhen, Guangdong, China

Abstract: Advances in cell and molecular biology have revolutionized vaccine development and drug delivery. This review explores how mechanisms such as receptor-mediated uptake, genetic engineering, and immune modulation inform the design of monoclonal antibody-based prophylactics and advanced delivery systems. We examine theoretical foundations including antigen–antibody recognition, endocytosis pathways, and techniques like phage display and mRNA vaccine platforms. Practical applications discussed include monoclonal antibodies for viral prevention and treatment, structure-based immunogens, and diverse delivery systems such as nanoparticles, antibody–drug conjugates, viral vectors, and cell-derived vesicles. Case studies, including COVID-19 mRNA vaccines and RSV-targeting antibodies, demonstrate how molecular design enhances delivery efficacy. We compare delivery platforms in terms of targeting, safety, and performance, and address current challenges such as biological barriers and regulatory complexity. Looking ahead, we highlight innovations like smart materials and synthetic biology. This review underscores how cellular and molecular principles are guiding the next generation of precise and effective medical interventions.

Keywords: cell biology; molecular biology; monoclonal antibodies; vaccines; drug delivery; nanomedicine; targeted therapy; immunotherapy

1. Introduction

Recent integration of cell biology, molecular biology, and pharmaceutical science has enabled the development of advanced vaccines and drug delivery systems once thought unattainable. Understanding cellular uptake, immune recognition, and gene expression now informs therapeutic design. Molecular biology techniques like genetic engineering and in vitro protein evolution support the creation of precise monoclonal antibodies and delivery platforms. Monoclonal antibodies are used in passive immunization and treatment of infections, cancer, and autoimmune diseases. Drug delivery technologies have advanced to include nanoparticles, immunomodulatory depots, and engineered cells. Receptor-mediated endocytosis guides nanoparticle uptake, while mRNA vaccines utilize cellular machinery for antigen production. B-cell biology and protein engineering have enabled high-affinity, modified antibodies with enhanced function. This review explores how these biological insights support monoclonal antibody-based therapies and drug delivery systems, with emphasis on the latter. It examines delivery platforms such as liposomes, exosomes, and viral vectors, alongside case studies including COVID-19 vaccines, nirsevimab, antibody–drug conjugates, and lipid nanoparticle gene therapies, while addressing challenges and future directions.

2. Cell and Molecular Biology Foundations for Therapeutic Design

2.1. Cellular Uptake and Trafficking Mechanisms

2.1.1. Sub Heading

A key factor in drug delivery and vaccine platforms like mRNA or viral vectors is how therapeutic agents enter and move within cells. Cell biology has identified pathways such as clathrin-mediated endocytosis, caveolin-dependent uptake, macropinocytosis, and phagocytosis that drug carriers can utilize or avoid [1]. Many nanoparticles use surface ligands to bind receptors and trigger uptake via clathrin-coated pits. Once internalized, effective delivery depends on endosomal escape to avoid lysosomal degradation. pH-sensitive or fusogenic materials enable release into the cytosol as endosomes acidify. Cationic polymers can trigger the proton sponge effect, aiding cytoplasmic release. For nuclear delivery, nuclear localization sequences guide transport.

Table 1. Major cellular uptake pathways and their relevance to drug delivery. CME: clathrin-mediated endocytosis; ER: endoplasmic reticulum.

Endocytic Pathway	Mechanism (Cell Biology)	Utilized by Delivery Systems	Refs
Clathrin-mediated endocytosis (CME)	Receptor-mediated vesicle formation via clathrin-coated pits. Capacity: tens of nanometers; Destination: endosomes/lysosomes.	Many ligand-targeted nanoparticles (e.g. antibody- or peptide-decorated liposomes) enter via CME when binding cell-surface receptors.	[1]
Caveolae-mediated endocytosis	Cholesterol-rich microdomains (caveolae) invaginate, often bypassing lysosomes. Destination: caveosomes, ER.	Certain lipid nanoparticles and virus-like particles exploit caveolae for cytosolic delivery (avoiding degradation).	[2]
Macropinocytosis	Non-specific engulfment of extracellular fluid; forms large vesicles. Triggered by growth factor signals, actin remodeling.	Cationic polymers and cell-penetrating peptide complexes can induce macropinocytosis, useful for delivering large nucleic acids.	[3,4]
Phagocytosis (in phagocytes)	Engulfment of particles (>500 nm) by immune cells (e.g. macrophages). Leads to phagolysosomal degradation.	Microspheres and vaccine adjuvant particles target antigen-presenting cells via phagocytosis for enhanced immune response.	[5]

As depicted in Figure 1, cells internalise extracellular cargo through four principals, mechanistically distinct pathways. Cells internalize extracellular cargo through four main endocytic pathways, each with distinct mechanisms and vesicle sizes. Clathrin-mediated endocytosis forms \~100 nm vesicles via receptor-ligand binding and is commonly used by antibody- or peptide-modified nanoparticles. Caveolae, small invaginations rich in caveolin, can bypass lysosomes and deliver cargo directly to the endoplasmic reticulum, aiding cytosolic delivery. Macropinocytosis engulfs extracellular fluid into large vesicles and often leads to lysosomal degradation, used by cationic polymers and peptide complexes. Phagocytosis, limited to phagocytes, engulfs larger particles for degradation and immune presentation. Understanding these pathways guides carrier design for optimal delivery and immune engagement.



Figure 1. Schematic overview of the four major endocytic pathways exploited in drug delivery.

Nanoparticle size and surface chemistry influence cellular uptake and intracellular fate, affecting drug efficacy [1]. Smaller PEGylated liposomes may enter via clathrin-mediated pathways, leading to lysosomal accumulation, while larger or albumin-coated particles may favor caveolar or macropinocytic uptake for better cytosolic delivery. Researchers use inhibitors or gene knockdowns to identify uptake mechanisms and guide carrier design, such as using transferrin ligands or cell-penetrating peptides. Transcytosis, where vesicles move cargo across cells, is key for crossing barriers like the blood–brain barrier. Targeting receptors like transferrin or insulin enables transport of drugs into the brain using antibody-conjugated carriers [6].

2.2. Immune Recognition and Molecular Immunology

Cell and molecular biology principles are equally vital on the vaccine side. A vaccine's goal is to elicit a protective immune response by delivering antigens that can be effectively presented to the immune system. Knowledge of how immune cells recognize and respond to antigens has guided both vaccine antigen design and the use of delivery systems as vaccine adjuvants. For example, antigen-presenting cells (dendritic cells, macrophages) patrol peripheral tissues and take up antigen, then migrate to lymph nodes to activate T-cells. This insight has informed vaccine delivery strategies, with antigen targeting to these cells shown to significantly enhance immunogenicity. Some modern vaccines use nanoparticles or liposomes that are sized and composed to be efficiently phagocytosed by dendritic cells in the skin or muscle [5,7]. Microneedle patch vaccines deposit antigens in the epidermis, where they are efficiently taken up by Langerhans cells (a specialized type of dendritic cell), leading to robust immunity even at lower doses [7]. Table 2 highlights how microneedle delivery compares to conventional injection:

Table 2. Comparison of vaccine delivery strategies and their interaction with the immune system. IM: intramuscular; SC: subcutaneous; APC: antigen-presenting cell.

Vaccine Delivery Method	Targeted immune cells	Advantages	Refs
Intramuscular injection	Muscle tissue, antigen diffuses to lymphatics; dendritic cells in muscle.	Established method; can deliver larger volumes. Drawback: much of	[8]

		antigen may not reach APCs efficiently.	
Microneedle patch (intradermal)	Langerhans cells and dermal dendritic cells in skin epidermis/dermis.	Highly immunogenic: skin APC density is high, leading to robust T and B cell response. Minimal pain; potentially self-administered patches.	[9]
Liposomal or nanoparticulate vaccine (various routes)	Depends on route (IM/SC or IV): often taken up by monocyte-derived dendritic cells, lymph node resident cells if directed.	Nanocarriers can protect antigens from degradation and co-deliver adjuvants. Can be engineered to drain to lymph nodes or be phagocytosed efficiently.	[5,10]

Understanding antigen structure and immune receptor interactions has advanced rational vaccine design. Structural studies of the RSV fusion protein revealed that its prefusion form elicits stronger neutralizing antibodies. Protein engineering was used to stabilize this form, enabling potent vaccine candidates and successful trials after years of setbacks. The same strategy was applied to stabilize coronavirus spike proteins for COVID-19 vaccines, preserving key neutralization-sensitive epitopes. Tools such as reverse vaccinology and bioinformatics now allow in silico identification of antigen targets by analyzing pathogen genomes and predicting surface proteins. This genome-based method, combined with high-throughput monoclonal antibody screening from recovered patients, has accelerated vaccine development for pathogens like meningococcus and coronaviruses [11]. In addition to antigen design, the delivery route influences vaccine efficacy. Dissolvable microneedle patches deliver cargo into the epidermis and superficial dermis, where antigen-presenting cells are abundant. Figure 2 shows how these patches penetrate shallow skin layers, avoiding deep tissue and enabling direct antigen uptake and lymphatic drainage.



Figure 2. Cross-section of a dissolvable microneedle patch delivering antigen to Langerhans and dermal dendritic cells.

Finally, innate immune sensing – how the body initially recognizes vaccine components – is another cell/molecular principle shaping vaccine design. Vaccine adjuvants work by engaging pattern recognition receptors (PRRs) on innate immune cells (e.g. Toll-

like receptors on dendritic cells) to trigger the danger signals that amplify immune response. Knowing this, scientists have developed new adjuvants that target specific PRRs. For instance, CpG oligodeoxynucleotides mimic bacterial DNA and activate TLR9 in dendritic cells and B cells, skewing the response toward a Th1 type immunity [8]. CpG has been formulated in vaccines for cancer and infectious diseases to enhance immunogenicity. Another modern adjuvant, AS01 (used in the Shingrix zoster vaccine and malaria vaccine), contains MPL (a TLR4 agonist) and a saponin (QS-21) in a liposomal formulation. This combination powerfully activates monocytes and dendritic cells by engaging their intrinsic danger-sensing pathways [8]. The result is a greatly improved antibody and T-cell response, as seen with Shingrix's >90% efficacy in older adults. These successes stem directly from the application of molecular immunology — identifying the key cytokines or immune signals required and designing molecules to induce them effectively. In summary, an intimate understanding of immune cell biology and molecular signaling is at the heart of modern vaccinology, ensuring vaccines not only contain the right antigen but also deliver the right activation signals to the immune system.

2.3. Genetic Engineering and Protein Design Techniques

Molecular biology techniques for manipulating DNA, RNA, and proteins are fundamental to developing monoclonal antibody therapies and engineered drug delivery systems. A key breakthrough was hybridoma technology, where B cells were fused with myeloma cells to create stable, antibody-producing lines. Initially producing murine antibodies, this approach evolved with gene cloning to yield humanized and fully human monoclonal antibodies using phage display or transgenic mice. Phage display expresses antibody fragments on bacteriophages, enabling selection of high-affinity binders without animal immunization. This method produced therapies like adalimumab and other antibodies for cancer and viral infections [5].

Advances in sequencing and synthesis further accelerated discovery. By analyzing B-cell repertoires from recovered patients, researchers identified potent neutralizing antibodies against pathogens like Ebola and SARS-CoV-2. These were rapidly cloned, expressed, and used therapeutically, as seen with COVID-19 antibodies such as REGN-COV2. Techniques like flow cytometry, gene cloning, and recombinant expression underpin these processes.

Molecular biology also supports drug delivery design. Virus-like particles (VLPs), produced by expressing viral structural proteins in cultured cells, mimic virus capsids without genetic material. They are used in vaccines and as delivery vehicles. The HPV vaccine, made from recombinant L1 VLPs in yeast, is a key example. Fusion proteins and peptide–drug conjugates are also engineered for targeted delivery. For example, tagraxofusp, an FDA-approved drug, is a fusion of IL-3 and diphtheria toxin that targets leukemia cells via the IL-3 receptor, produced through gene fusion and bacterial expression.

Emerging tools like CRISPR-Cas9 combine gene editing with advanced delivery. Lipid nanoparticles deliver mRNA encoding Cas9 and guide RNA to liver cells, achieving in vivo gene knockdown, as demonstrated in a clinical trial for transthyretin amyloidosis. These innovations reflect the integration of molecular biology with delivery technologies to create sophisticated and precise therapeutics.

With these foundations established, the following sections explore applications of monoclonal antibody-based vaccines and prophylactics, followed by an in-depth discussion of strategies in advanced drug delivery systems.

3. Monoclonal Antibodies and Vaccine Development: From Principles to Practice

3.1. Cellular Uptake and Trafficking Mechanisms

Monoclonal antibodies (mAbs) have become a key class of biologic drugs used to treat cancers, autoimmune diseases, and infections. They are also used in passive immunization by directly neutralizing pathogens. Their development has been significantly advanced by cellular and molecular biology.

3.1.1. From Hybridomas to Engineered Antibodies

Hybridoma technology was the first practical method to produce monoclonal antibodies by fusing B cells with myeloma cells. However, early murine antibodies were immunogenic in humans. Molecular biology enabled gene cloning to replace mouse constant regions with human ones, creating chimeric and eventually humanized antibodies. Structural insights, including the definition of complementarity-determining regions (CDRs), and recombinant DNA methods facilitated these developments.

Fully human antibodies are now produced using in vitro display libraries or transgenic animals. Phage display allows the selection of high-affinity binders from libraries of billions of antibody fragments. Adalimumab, the first fully human antibody from this method, exemplifies its success. Transgenic mice with human immunoglobulin loci produce human-sequence antibodies, used in therapies such as palivizumab for RSV.

3.1.2. Enhancing Antibody Function by Design

Molecular engineering allows antibodies to be customized for function. Fc region glycosylation or sequence modifications can enhance or reduce immune effector functions. For instance, afucosylated antibodies show improved antibody-dependent cellular cytotoxicity (ADCC) due to stronger binding to FcγRIII receptors on NK cells. Conversely, point mutations like LALA can minimize Fc receptor interaction to avoid unwanted inflammation.

Bispecific antibodies bind two different targets simultaneously. BiTEs (bispecific T-cell engagers) link a tumor antigen with CD3 on T cells to mediate tumor cell killing. Their design required innovations in fragment pairing and expression systems, including structural solutions like “knobs-into-holes” mutations to ensure correct heavy chain pairing. These formats represent a new wave of antibody-based therapeutics.

3.1.3. Monoclonal Antibodies in Immunoprophylaxis

mAbs are now used as passive immunization tools for infectious diseases where vaccines are limited. Palivizumab was approved to prevent RSV in high-risk infants. Nirsevimab, a next-generation mAb, binds the prefusion RSV F protein with high affinity and includes an Fc region modified with the YTE mutation to extend half-life in infants by enhancing neonatal Fc receptor recycling [12]. A single dose protects infants over an entire RSV season, with 75–80% efficacy in trials [13].

During COVID-19, mAbs like REGEN-COV and sotrovimab were rapidly developed using high-throughput B cell sequencing and structural optimization. Although viral variants impacted some efficacy, the rapid turnaround from sequence to therapy demonstrated the power of molecular biology in therapeutic development [14].

3.1.4. Safety and Immune Considerations

Cellular and molecular knowledge also mitigates safety concerns such as immunogenicity and off-target effects. De-immunization strategies remove or silence T-cell epitopes, while human protein scaffolds further reduce immune rejection.

In summary, monoclonal antibody development exemplifies the synergy between cell biology and therapeutic innovation. From hybridomas to humanized and bispecific

formats, advances in molecular engineering have turned antibodies into versatile therapeutic tools. Ongoing efforts now explore gene therapy approaches where viral vectors deliver antibody genes to allow long-term in vivo expression, as shown in AAV-based delivery of anti-HIV antibodies. This integration of antibody design and drug delivery represents the future of long-acting biological therapy.

3.2. Innovations in Vaccine Technology and Delivery

Traditional vaccines, including live-attenuated, inactivated, and subunit types, have proven effective but often face challenges in speed of development and limited efficacy against some pathogens. Molecular biology has revolutionized this field, enabling novel platforms such as nucleic acid vaccines, viral vectors, and advanced adjuvants.

3.2.1. mRNA Vaccines

The COVID-19 pandemic demonstrated the potential of mRNA vaccine technology. These vaccines deliver modified messenger RNA encoding viral antigens via lipid nanoparticles (LNPs). Once inside cells, the mRNA is translated into antigenic proteins that elicit immune responses [5].

Chemical modifications, such as replacing uridine with pseudouridine, reduce innate immune activation and improve protein translation. Codon optimization and the inclusion of untranslated regions enhance mRNA stability and expression. The SARS-CoV-2 spike gene used in vaccines was designed with these optimizations.

LNPs protect the mRNA and facilitate cellular uptake. They include ionizable lipids that help the mRNA escape endosomes after endocytosis, a critical process guided by knowledge of cellular trafficking. This enabled rapid vaccine development — SARS-CoV-2 mRNA vaccines entered clinical trials within weeks of sequence identification.

mRNA vaccines are also adaptable. Updated COVID-19 booster shots targeting new variants were produced within months, demonstrating flexibility unmatched by traditional platforms. These vaccines elicit both B cell and T cell responses, engaging both MHC class I and II pathways.

Challenges remain, such as cold-chain storage and mild reactogenicity, but ongoing optimization aims to improve formulation stability and reduce side effects. The success of COVID-19 vaccines has led to clinical trials for mRNA vaccines targeting influenza, Zika, HIV, and personalized cancer therapy.

3.2.2. Viral Vector Vaccines

Viral vectors, such as adenovirus and vesicular stomatitis virus (VSV), are engineered to deliver genes encoding pathogen antigens. This method mimics infection by expressing antigens inside cells, stimulating strong immune responses. The Ebola vaccine (Ervebo), based on VSV expressing Ebola glycoprotein, achieved near 100% efficacy in outbreak trials.

The Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines used chimpanzee and human adenovirus vectors to express SARS-CoV-2 spike protein. These vectors were developed through molecular cloning and scaled using mammalian cell culture systems [14]. While vector immunity and limitations on boosting exist, heterologous prime-boost strategies and rare serotype vectors help address these challenges.

3.2.3. Protein Subunit and Nanoparticle Vaccines

Recombinant protein vaccines are being enhanced through structural design and nanotechnology. Novavax's COVID-19 vaccine uses a genetically engineered, stabilized spike protein that assembles into nanoparticles. These mimic viral surfaces, increasing B cell activation and antibody responses [15,16].

Mosaic nanoparticle vaccines display antigens from multiple strains on a single particle to induce broadly neutralizing antibodies. Ferritin-based nanocages genetically fused

with antigen variants are a prominent example. These advances leverage molecular cloning and immune repertoire insights.

3.2.4. Advanced Adjuvants and Delivery Systems for Vaccines

New adjuvants have emerged from a deeper understanding of innate immunity. Emulsion adjuvants like MF59 recruit immune cells, while Toll-like receptor (TLR) agonists such as CpG and imiquimod are incorporated into formulations for enhanced activation [8]. AS04, used in the HPV vaccine, combines alum with a TLR4 agonist to improve response quality.

Innovative delivery methods also improve vaccine targeting. Oral vaccines use enteric coatings or live vectors to engage gut-associated lymphoid tissue, while inhaled vaccines target respiratory mucosa. These approaches are based on knowledge of mucosal immunology and barrier penetration.

In conclusion, vaccine technology has evolved from empirical formulations to rational design. Modern vaccines are engineered at the molecular level — from selecting stabilized antigen sequences to tailoring delivery platforms and adjuvants. These advancements have enabled faster responses to emerging threats like COVID-19 and hold promise for diseases lacking effective vaccines, such as HIV and tuberculosis. Emerging strategies include gene-encoded vaccines and universal vaccine designs, all built on a foundation of molecular and cellular biology.

4. Drug Delivery Systems: Principles, Platforms, and Case Studies

Drug delivery science seeks to ensure that therapeutic molecules reach their intended site of action in the body at optimal concentrations and appropriate times, with minimal off-target effects. Traditional drug administration often suffers from issues like poor solubility, rapid clearance, or systemic toxicity due to distribution to non-target tissues [17]. By applying cell and molecular biology principles, researchers have created advanced drug delivery systems (DDS) that overcome these challenges. These systems range from nano-sized carriers that ferry drugs to specific cells, to biomaterials that release drugs over months, to conjugates that become activated only in diseased tissue. Here we examine key categories of delivery systems – nanoparticle carriers, biologically-derived vesicles, conjugated prodrugs, and stimuli-responsive matrices – and highlight how their design is informed by biological mechanisms. Table 3 provides an overview of several delivery system types and their characteristics.

Table 3. Examples of Drug Delivery System Platforms and Their Features.

Delivery System	Composition & Size	Targeting Mechanism	Therapeutic Uses & Examples	Refs
Liposomes (conventional & long-circulating)	Spherical lipid bilayer vesicles (50–200 nm). Often PEGylated for "stealth".	Passive targeting via Enhanced Permeability and Retention (EPR) in tumors; can be functionalized with ligands for active targeting.	Doxil (PEGylated liposomal doxorubicin) – first FDA-approved nanomedicine for cancer, improving drug retention and reducing cardiac toxicity. Also used for fungal infections (Ambisome).	[10]
Polymeric Nanoparticles/Micelles	Biodegradable polymer-based carriers (e.g. PLGA nanoparticles 100–200 nm; or self-assembled	Size and surface properties cause passive accumulation in tumor tissue (EPR). Can attach antibodies or peptides for active	Abraxane (albumin-bound paclitaxel nano-micelles) – nanoparticle improving solubility and tumor delivery of paclitaxel. Polymeric nanosystems for siRNA (in	[17, 18]

	block-copolymer micelles ~20–100 nm).	targeting to cell receptors.	clinical trials) use targeted ligands for cell uptake.	
Dendrimers	Highly branched synthetic polymers (~5–10 nm diameter for generation 5–7 dendrimers). Nanometer-scale.	Multi-valent surface allows attachment of targeting ligands and drugs. Can precisely engineer size and surface charge.	Experimental dendrimer-drug conjugates for cancer and inflammation; VivaGel (dendrimer microbicide for HIV) reached clinical trials. Dendrimers can target tumor cells or infective agents by functionalizing with specific ligands.	[17]
Exosomes & Cell-Derived Vesicles	Nanoscale vesicles (30–150 nm) secreted by cells, containing lipids, proteins, RNA. Can be purified and loaded with drugs.	Innate homing abilities: e.g. exosomes from certain cells might home to the tissue of origin. Low immunogenicity allows evasion of immune clearance. Can be surface-decorated by engineering parent cells.	Being explored for delivering siRNA, miRNA, or small drugs for cancer and neurodegenerative diseases. ExoSTING (exosome loaded with STING agonist) is an immunotherapy in trials. Exosomes can cross biological barriers like the blood–brain barrier more readily due to their cell-derived membranes.	[5]
Viral Vectors (for gene delivery)	Modified viruses (e.g. Adenovirus, AAV ~20 nm, Lentivirus) carrying therapeutic genes.	Natural tropism can be retargeted by pseudotyping or engineered surface proteins to infect specific cell types. AAV serotypes show tissue preferences (AAV9 -> muscle/liver, etc.).	Gene therapy: e.g. AAV-based Zolgensma delivers a functional SMA gene to motor neurons (one-time cure for spinal atrophy); Adenoviral vectors in oncolytic therapy (Imlygic) or vaccines (J&J COVID-19 vaccine). They achieve long-term expression of therapeutic proteins after a single administration.	[13]
Antibody–Drug Conjugates (ADCs)	Monoclonal antibody specific to a target (e.g. a tumor antigen), chemically linked to a potent drug (toxins, chemo) via a cleavable linker. Technically nanoscale (~<10 nm) but often considered molecular conjugates.	Active targeting: Antibody binds antigen on target cell, ADC is internalized, and drug is released intracellularly (linker cleaved by pH or enzymes). Bystander effect possible if drug diffuses to neighboring cells.	15 ADCs approved for cancers as of 2025 (e.g. T-DM1 for breast cancer targets HER2; Brentuximab vedotin for lymphoma targets CD30). Dramatically increases drug concentration in target cells while sparing normal cells, improving therapeutic index. Also in trials: immunosuppressive ADCs for autoimmune diseases.	[19]

Stimuli-Responsive "Smart" Systems	Various forms: hydrogels, polymer implants, or nanoparticles that respond to a trigger (pH, temperature, enzymes, light) to release drug. E.g. pH-sensitive polymer that dissolves in acidic tumor microenvironment.	Triggered release: Exploits differences between target site and normal tissue (low pH in endosomes or tumors; overexpressed enzymes in cancer; external triggers like focused heat or ultrasound). Ensures minimal release until the system encounters the trigger at target.	Examples: pH-responsive polymer micelles releasing chemo drugs in acidic tumor milieu (in development); Glucose-responsive insulin delivery hydrogels (release insulin when glucose levels rise); Implantable gels that release arthritis drugs when inflammation-associated enzymes are present. Ultrasonically-triggered microbubbles to enhance tissue uptake of drugs (research stage).	[18]
Implantable Controlled-Release Devices	Solid polymer implants or pumps that are placed in specific tissue, releasing drug at a controlled rate over long durations. (Size: macroscopic, a few mm or cm).	Localized delivery: placed directly at target site (e.g. tumor resection cavity, or under skin for systemic slow release). Zero-order kinetics achievable by design (constant release rate). Some electronically controlled pumps can be triggered externally.	Gliadel wafer (biodegradable polymer implant releasing carmustine in brain tumor bed); Norplant (levonorgestrel contraceptive rods providing 5-year drug release); Insulin pumps and emerging closed-loop systems. Reduces systemic exposure and improves patient compliance by infrequent dosing.	[17]

Table 3. distills four emblematic delivery platforms and the biological cues they exploit. Clockwise from top-left: (i) a PEGylated liposome that relies on the tumour's leaky vasculature for passive accumulation (EPR effect); (ii) a lipid-nanoparticle (LNP) encapsulating mRNA, engineered to respond to the low pH of endosomes and trigger membrane disruption for cytosolic release; (iii) a stimuli-responsive hydrogel or implant that can be activated by light, ultrasound or local glucose levels to deliver its payload on demand; and (iv) an antibody-drug conjugate (ADC) in which a cleavable linker — sensitive to lysosomal enzymes or acidic pH — frees a highly potent toxin only inside target cells. Together these panels illustrate the central design logic of modern DDS: combine molecular specificity (ligand, linker, or polymer chemistry) with a disease-site trigger to maximise on-target exposure while sparing healthy tissue.These diverse systems highlight how understanding the pathophysiology of disease and cellular microenvironments guides delivery design. For instance, tumors often exhibit leaky vasculature and poor lymphatic drainage – the basis of the EPR effect. Researchers exploited this property by designing nanocarriers of approximately 100 nm in size that preferentially accumulate in tumors (passive targeting) [20]. However, they also learned that the EPR effect can be variable in human tumors [20]. To address that, active targeting moieties (like antibodies against tumor antigens) are added to nanoparticles to improve uptake by cancer cells directly, not solely relying on passive diffusion [19]. In designing ADCs, knowledge that certain proteases are abundant in the target cell has led to the development of linkers that only cleave in that environment (e.g. cathepsin-cleavable linkers release drug predominantly inside lysosomes of the target cell) [19].



Figure 3. Representative nanocarrier architectures and their targeting/trigger mechanisms.

4.1. Nanoparticle Systems in Action

A milestone in nanomedicine was the approval of Doxil in 1995, a formulation of doxorubicin encapsulated in PEGylated liposomes. The PEG coating reduces uptake by the immune system, prolonging circulation and enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect [21]. Doxil reduced cardiotoxicity compared to free doxorubicin and marked a turning point for nanocarrier validation. Ambisome, a liposomal amphotericin B, similarly reduced nephrotoxicity by targeting fungal-infected tissues.

Polymeric micelles have enabled the delivery of poorly soluble drugs like paclitaxel. Abraxane, an albumin-bound formulation of paclitaxel, bypasses toxic solvents and exploits albumin's affinity for tumor-associated proteins, improving tumor uptake and reducing side effects [1].

4.2. Targeted and Self-Guided Systems

Cell biology and immunology have guided the creation of targeted delivery systems. Antibodies on nanoparticles enable specific targeting, as seen in antibody-drug conjugates (ADCs) and immunoliposomes. Aptamers, short nucleic acid sequences that fold into specific structures, offer an alternative. Pegaptanib, an aptamer approved for macular degeneration, illustrates their clinical potential. Aptamer selection is achieved using SELEX, a process rooted in molecular biology that enables high-specificity binding agents to be developed for cancer targeting.

4.3. Biologically Inspired Carriers

Exosomes, naturally secreted vesicles involved in intercellular communication, serve as promising drug carriers due to their biocompatibility and ability to transfer proteins

and RNA. Drugs such as small interfering RNAs (siRNAs) can be loaded into exosomes or expressed in donor cells via genetic fusion to membrane proteins. Surface modifications, like attaching targeting peptides to Lamp2b, allow exosomes to be directed to specific tissues. Exosomes have demonstrated superior brain penetration in preclinical studies compared to synthetic carriers, although scale-up and uniformity remain technical challenges [5].

4.4. Responsive and Smart Delivery

Responsive systems are designed to release drugs in specific physiological environments. Tumors often have a slightly acidic microenvironment, which can be exploited using pH-sensitive carriers that release drugs under acidic conditions. These include liposomes or polymers that degrade or change configuration when pH drops below 6.8. For example, doxorubicin-loaded liposomes destabilize in acidic endosomes, enhancing intracellular delivery [5].

Enzyme-responsive systems utilize overexpressed enzymes in diseased tissue to activate or release drugs. Matrix metalloproteinases (MMPs) are commonly targeted; for instance, MMP-cleavable linkers can release drugs selectively in tumors.

External triggers such as ultrasound and light also enable localized delivery. Focused ultrasound with microbubbles can transiently open the blood–brain barrier, allowing drugs to access brain tissue . Photodynamic therapy uses light-activated agents to generate cytotoxic species, while gold nanoshells heated by near-infrared light can trigger drug release from hydrogels. Magnetic nanoparticles can be guided or heated by magnetic fields to induce hyperthermia and local drug release.

These "smart" systems often mimic biological processes, such as platelet activation at injury sites. Inspired by such mechanisms, materials are now designed to release therapeutic agents in response to biological cues like thrombin.

4.5. Ccase Study: Crispr-CAS9 Delivery

CRISPR-Cas9 gene editing requires intracellular delivery of a protein and guide RNA, which cannot penetrate cell membranes unaided. In 2021, a landmark study achieved in vivo editing by encapsulating Cas9 mRNA and guide RNA in lipid nanoparticles. Delivered intravenously, the formulation achieved over 50% gene editing in hepatocytes by targeting the transthyretin (TTR) gene, reducing pathogenic protein levels [22,23]. This was enabled by optimized LNP formulations and mRNA modifications also used in mRNA vaccines. The result was the first in-human gene editing treatment delivered systemically.

4.6. Safety and Challenges

Despite their promise, nanoparticle systems face biological barriers. Macrophages in the liver and spleen rapidly clear nanoparticles, reducing drug efficacy and potentially causing toxicity. To evade this, PEGylation is used to reduce immune recognition [23]. Particle size, shape, and stiffness also influence clearance; for example, flexible filomicelles circulate longer than spherical particles.

Some patients develop anti-PEG antibodies after repeated dosing, leading to accelerated blood clearance (ABC phenomenon). Immune compatibility thus remains a key concern in chronic therapy.

For viral vectors, immune responses against the vector or transduced cells limit their reuse. This has led to increased interest in non-viral alternatives like LNPs, drawing from siRNA and mRNA delivery strategies.

4.7. Epr Effect Revisited

The EPR effect, long considered a reliable mechanism for nanoparticle accumulation in tumors, has proven variable in clinical settings. Not all human tumors are sufficiently

"leaky" to allow nanoparticle entry [20]. Strategies like tumor priming — modulating vascular permeability or tumor stroma — can enhance EPR. Imaging-based assessments may guide personalized use: if a patient's tumor shows poor nanoparticle uptake, alternative therapies may be preferred.

4.8. Integration with Electronics and Devices

Drug delivery is also advancing through integration with electronic devices. Controlled-release microchips can be triggered electronically to release precise doses, such as pulsatile parathyroid hormone for osteoporosis. Closed-loop insulin delivery systems simulate pancreatic function using real-time glucose monitoring and infusion pumps. Though more device-based, these systems share the same goal: biologically responsive, optimized drug administration.

In summary, modern drug delivery integrates deep knowledge of cellular processes with material science to overcome biological barriers. Each delivery system is shaped by the properties of the drug and the disease context. For example, Patisiran, the first approved siRNA drug, succeeded because of lipid nanoparticle delivery to the liver. Similar delivery technologies are now being explored for targeting other organs like the lungs or bone marrow.

The clinical impact is already evident. Zolgensma, an AAV9 gene therapy for spinal muscular atrophy, crosses the blood–brain barrier to deliver a functional SMN1 gene to motor neurons. It significantly improves survival in infants with this lethal disorder . Similarly, antibody-drug conjugates (ADCs) like trastuzumab emtansine (T-DM1) deliver cytotoxic agents to cancer cells with improved specificity. T-DM1 uses a thioether linker that remains stable in circulation but is cleaved in lysosomes, demonstrating how knowledge of intracellular trafficking guides molecular design [19].

As summarized in Table 3 of the original text, no single delivery platform suits all applications. Cancer treatment might combine nanoparticles, ADCs, or engineered cells. Chronic diseases may benefit from long-acting implants, while infectious diseases could use targeted antibiotic carriers. Across these use cases, the central theme remains: leveraging cellular mechanisms enhances the precision and safety of therapy.

5. Future Perspectives and Conclusion

The integration of cell biology and molecular biology with biomedical engineering has transformed the development of vaccines and drug delivery systems. As seen in innovations like mRNA vaccines, antibody–drug conjugates, and nanocarriers, biology-guided design has become a foundational strategy. Looking ahead, several key trends are shaping the future of therapeutic development.

Medicine is shifting toward individualized approaches, and drug delivery is following suit. Personalized cancer vaccines using neoantigen peptides specific to a patient's tumor are one example. Delivery systems, such as mRNA or nanoparticles, can be adapted to stimulate immune responses tailored to each tumor. Similarly, tumor imaging could guide the decision to use nanoparticle-based treatments, depending on uptake efficiency.

Genomic and proteomic profiling can reveal unique cell-surface markers in diseased tissues, enabling the use of ligand- or antibody-targeted delivery vehicles. This concept supports the design of patient-specific nanomedicines, enhancing treatment precision and efficacy.

Cell-based therapies are expanding the scope of drug delivery. CAR-T cells are genetically engineered immune cells that target and eliminate cancer cells. This process depends entirely on cellular and molecular tools for gene insertion and immune modulation. Beyond CAR-T, microbes are being engineered to colonize disease sites and release therapeutic compounds in situ.

Other strategies involve using macrophages or stem cells as delivery vehicles. These cells can be loaded with drugs or engineered to secrete therapeutic proteins in targeted

tissues. For example, mesenchymal stem cells have been modified to deliver enzymes or anti-inflammatory agents to disease sites.

Synthetic biology is making these systems more responsive. Cells can be programmed with gene circuits to sense pathological cues — like low oxygen or high interleukin levels — and express therapeutic proteins only under specific conditions. These "smart" systems offer tight spatial and temporal control of treatment.

Effective delivery to challenging areas such as the brain, solid tumors, or intracellular compartments remains a major goal. Nanoparticles designed to cross the blood–brain barrier are under investigation, including those that exploit receptor-mediated transport or use ultrasound to open tight junctions.

In solid tumors, modifying the tumor microenvironment can enhance drug penetration. Co-delivery of collagen-degrading enzymes or vascular normalizing agents with nanoparticles is one approach. At the cellular level, improving endosomal escape of macromolecular drugs is also critical. Strategies include incorporating pH-responsive peptides or using electroporation and nanoneedles to deliver cargo directly into the cytosol.

As therapies become more integrated with biological systems, distinguishing drug from body becomes difficult. This raises safety concerns. Long-term monitoring is necessary for interventions like gene editing or persistent viral vectors. Immune responses to novel materials, such as nanocarriers, must be carefully evaluated.

The immune system may also be leveraged in delivery. For example, nanoparticles can be temporarily attached to circulating immune cells, delivering drugs to inflammation sites. However, these complex systems challenge existing regulatory frameworks. Many therapies now combine biologics, drugs, and devices, requiring interdisciplinary oversight and expertise.

Advanced drug delivery systems may soon be coupled with digital tools for real-time feedback and control. Closed-loop insulin pumps already mimic pancreatic regulation. Similar systems could be developed for cancer or immunotherapy, using biosensors to modulate drug release based on biomarker levels. Achieving this requires molecular biology-based sensors and programmable release technologies.

The development of modern therapeutics relies on collaboration across biology, chemistry, materials science, and clinical medicine. The success of mRNA vaccines during the COVID-19 pandemic demonstrated the power of interdisciplinary efforts, combining mRNA optimization, lipid chemistry, and immunological insight.

Understanding molecular structure guides therapeutic design. Knowing how cells internalize and process materials informs delivery strategies. Expertise in material science enables formulation of effective carriers. These combined efforts are essential to bringing new therapies to patients.

The application of cell and molecular biology has revolutionized our ability to design targeted, efficient, and safer therapies. Monoclonal antibodies, for example, leverage immune specificity, while nanoparticle carriers enable precise control over drug distribution. Gene therapy and mRNA-based treatments are now curing diseases that were once untreatable, such as spinal muscular atrophy.

Although not every innovation will succeed universally — challenges like the variability of EPR in nanoparticle delivery remain— the overall direction is clear. Better understanding of biological systems enables better interventions. As research uncovers new cellular targets and mechanisms, and as technology enables their exploitation, future treatments will become more intelligent, adaptive, and integrated with the human body.

The story of smart vaccines and precision drug systems underscores a simple principle: the more we understand the biology, the more precisely we can treat disease. Continued exploration at the molecular and cellular levels will lead to therapies that are not only more effective, but also more aligned with the needs of individual patients worldwide.

References

1. Y. Ju, et al., "Application of advances in endocytosis and membrane trafficking to drug delivery," *Adv. Drug Deliv. Rev.*, vol. 157, pp. 118–141, 2020, doi: 10.1016/j.addr.2020.07.026.
2. K. Swetha, et al., "Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines," *Vaccines*, vol. 11, no. 3, p. 658, 2023, doi: 10.3390/vaccines11030658.
3. W. Liu, et al., "Theoretical basis, state and challenges of living cell-based drug delivery systems," *Theranostics*, vol. 14, no. 13, pp. 5152–5170, 2024, doi: 10.7150/thno.99257.
4. R. Neupane, et al., "Endocytic highways: Navigating macropinocytosis and other endocytic routes for precision drug delivery," *Int. J. Pharm.*, 2025, p. 125356, doi: 10.1016/j.ijpharm.2025.125356.
5. H. Chen, et al., "Exosomes, a new star for targeted delivery," *Front. Cell Dev. Biol.*, vol. 9, p. 751079, 2021, doi: 10.3389/fcell.2021.751079.
6. K. D. R. Roth, et al., "Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy," *Front. Cell Infect. Microbiol.*, vol. 11, p. 697876, 2021, doi: 10.3389/fcimb.2021.697876.
7. I. Menon, et al., "Microneedles: A new generation vaccine delivery system," *Micromachines*, vol. 12, no. 4, p. 435, 2021, doi: 10.3390/mi12040435.
8. M. Singh and D. O'Hagan, "Advances in vaccine adjuvants," *Nat. Biotechnol.*, vol. 17, no. 11, pp. 1075–1081, 1999, doi: 10.1038/15058.
9. S. Zhou, et al., "Emerging microelectronic microneedles (eMN) for biomedical applications," *J. Mater. Chem. C*, vol. 12, no. 27, pp. 9868–9887, 2024, doi: 10.1039/D4TC01576B.
10. H. Nsairat, et al., "Liposomes: Structure, composition, types, and clinical applications," *Heliyon*, vol. 8, no. 5, p. e09394, 2022, doi: 10.1016/j.heliyon.2022.e09394.
11. I. N. Weerarathna, et al., "Prophylactic and therapeutic vaccine development: Advancements and challenges," *Mol. Biomed.*, vol. 5, no. 1, p. 57, 2024, doi: 10.1186/s43556-024-00222-x.
12. B. Resch, "Nirsevimab for respiratory syncytial virus prophylaxis in newborns and infants," *NEJM Evid.*, vol. 4, no. 3, p. EVIDe2400440, 2025. , doi: 10.1056/EVIDe2400440.
13. S. B. Drysdale, et al., "Nirsevimab for prevention of hospitalizations due to RSV in infants," *N. Engl. J. Med.*, vol. 389, no. 26, pp. 2425–2435, 2023, doi: 10.1056/NEJMoa2309189.
14. E. Fang, et al., "Advances in COVID-19 mRNA vaccine development," *Signal Transduct. Target. Ther.*, vol. 7, no. 1, p. 94, 2022, doi: 10.1038/s41392-022-00950-y.
15. Y. Yang, et al., "DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection," *npj Vaccines*, vol. 9, no. 1, p. 258, 2024, doi: 10.1038/s41541-024-01059-9.
16. M. F. Bachmann, et al., "Virus-like particles: A versatile and effective vaccine platform," *Expert Rev. Vaccines*, vol. 24, no. 1, pp. 444–456, 2025, doi: 10.1080/14760584.2025.2508517.
17.] S. Adepu and S. Ramakrishna, "Controlled drug delivery systems: Current status and future directions," *Molecules*, vol. 26, no. 19, p. 5905, 2021, doi: 10.3390/molecules26195905.
18. S. Chu, et al., "pH-responsive polymer nanomaterials for tumor therapy," *Front. Oncol.*, vol. 12, p. 855019, 2022, doi: 10.3389/fonc.2022.855019.
19. R. Wang, et al., "Antibody–Drug Conjugates (ADCs): Current and future biopharmaceuticals," *J. Hematol. Oncol.*, vol. 18, no. 1, p. 51, 2025
20. Y. Shi, et al., "The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy," *Theranostics*, vol. 10, no. 17, pp. 7921–7942, 2020.
21. Q. Liu, et al., "Current research trends of nanomedicines," Acta Pharm. Sin. B, vol. 13, no. 11, pp. 4391–4416, 2023
22. M. Fontana, et al., "CRISPR-Cas9 gene editing with Nexiguran Ziclumeran for ATTR cardiomyopathy," *N. Engl. J. Med.*, vol. 391, no. 23, pp. 2231–2241, 2024, doi: 10.1056/NEJMoa2412309.
23. J. D. Gillmore, et al., "CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis," *N. Engl. J. Med.*, vol. 385, no. 6, pp. 493–502, 2021, doi: 10.1056/NEJMoa2107454.